Nobunao Wakabayashi

Nobunao Wakabayashi

Auto-generated profile, based on publicly available information

Nobunao Wakabayashi

Department of Pharmacology and Chemical Biology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2010 in Science Signaling
Verified
Journal Article
Closed access
PDF file
NWNobunao Wakabayashi
Nobunao Wakabayashi
SSSoona Shin
Soona Shin
SSStephen L. Slocum
Stephen L. Slocum
EAElin S. Agoston
Elin S. Agoston
JWJunko Wakabayashi
Junko Wakabayashi
TKThomas W. Kensler
Thomas W. Kensler
The Keap1-Nrf2-ARE signaling pathway elicits an adaptive response for cell survival after endogenous and exogenous stresses, such as inflammation and carcinogens, respectively. Keap1 inhibits the transcriptional activation activity of Nrf2 (p45 nuclear factor erythroid-derived 2–related factor 2) in unstressed cells by facilitating its degradation. Through transcriptional analyses in Keap1- or Nrf2-disrupted mice, we identified interactions between the Keap1-Nrf2-ARE and the Notch1 signaling pathways. We found that Nrf2 recognized a functional antioxidant response element (ARE) in the promoter of Notch1. Notch1 regulates processes such as proliferation and cell fate decisions. We report a functional role for this cross talk between the two pathways and show that disruption of Nrf2 impeded liver regeneration after partial hepatectomy and was rescued by reestablishment of Notch1 signaling.

1 February 2014 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
NWNobunao Wakabayashi
Nobunao Wakabayashi
JSJohn J. Skoko
John J. Skoko
DCDionysios V. Chartoumpekis
Dionysios V. Chartoumpekis
SKShoko Kimura
Shoko Kimura
SSStephen L. Slocum
Stephen L. Slocum
TKThomas W. Kensler
Thomas W. Kensler
The Notch signaling pathway enables regulation and control of development, differentiation, and homeostasis through cell-cell communication. Our investigation shows that Notch signaling directly activates the Nrf2 stress adaptive response pathway through recruitment of the Notch intracellular domain (NICD) transcriptosome to a conserved Rbpjκ site in the promoter of Nrf2. Stimulation of Notch signaling through Notch ligand expression in cells and by overexpression of the NICD in RosaNICD/−::AlbCre mice in vivo induces expression of Nrf2 and its target genes. Continuous and transient NICD expression in the liver produces a Notch-dependent cytoprotective response through direct transcriptional activation of Nrf2 signaling to rescue mice from acute acetaminophen toxicity. This response can be reversed upon genetic disruption of Nrf2. Morphological studies showed that the characteristic phenotype of high-density intrahepatic bile ducts and enlarged liver in RosaNICD/−::AlbCre mice could be at least partially reversed after Nrf2 disruption. Furthermore, the liver and bile duct phenotypes could be recapitulated with constitutive activation of Nrf2 signaling in Keap1F/F::AlbCre mice. It appears that Notch-to-Nrf2 signaling is another important determinant in liver development and function and promotes cell-cell cytoprotective signaling responses.

1 November 2015 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
NWNobunao Wakabayashi
Nobunao Wakabayashi
DCDionysios V. Chartoumpekis
Dionysios V. Chartoumpekis
TKThomas W. Kensler
Thomas W. Kensler

8 March 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
DCDionysios V. Chartoumpekis
Dionysios V. Chartoumpekis
YYYoko Yagishita
Yoko Yagishita
MFMarco Fazzari
Marco Fazzari
Dushani L PalliyaguruDushani L Palliyaguru
Dushani L Palliyaguru
URUma N.M. Rao
Uma N.M. Rao
NWNobunao Wakabayashi
Nobunao Wakabayashi
Insulin resistance is associated with increased incidence and enhanced progression of cancers. However, little is known about strategies that can effectively ameliorate insulin resistance and consequently halt cancer progression. Herein, we propose that the transcription factor Nrf2 (also known as Nfe2l2) may be such a target, given its central role in disease prevention. To this end, we developed a mouse that overexpresses the Notch intracellular domain in adipocytes (AdNICD), leading to lipodystrophy-induced severe insulin resistance and subsequent development of sarcomas, as a model reflecting that Notch signaling is deregulated in cancers and shows positive associations with insulin resistance and fatty liver disease in humans. Nrf2 pathway activation was achieved by knocking down Keap1, a repressor of Nrf2, in the AdNICD background. Constitutively enhanced Nrf2 signaling in this setting led to prevention of hepatic steatosis, dyslipidemia, and insulin resistance by repressing hepatic lipogenic pathways and restoration of the hepatic fatty acid profile to control levels. This protective effect of Nrf2 against diabetes extended to significant reduction and delay in sarcoma incidence and latency. Our study highlights that the Nrf2 pathway, which has been induced by small molecules in clinical trials, is a potential therapeutic target against insulin resistance and subsequent risk of cancer.